Hutchison China MediTech Ltd – ADR (NASDAQ:HCM) has been upgraded to Hold in a statement by Zacks Investment Research today.
- Updated: October 9, 2016
Zacks Investment Research has upgraded Hutchison China MediTech Ltd – ADR (NASDAQ:HCM) to Hold in a report released on 10/05/2016.
Just yesterday Hutchison China MediTech Ltd – ADR (NASDAQ:HCM) traded -0.84% lower at $12.21. Hutchison China MediTech Ltd – ADR’s 50-day moving average is $12.36 and its 200-day moving average is $12.99. The last closing price is down -9.10% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 202,453 shares of HCM traded hands, up from an average trading volume of 37,105
Recent Performance Chart
Hutchison China MediTech Ltd – ADR has one year low of $9.80 and a one year high of $14.70 and has a total market value of $0.
More About Hutchison China MediTech Ltd – ADR (NASDAQ:HCM)
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.